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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Introduction
It has been increasingly recognized that diabetes mellitus is an important vascular 
disease in patients with heart failure and cardiomyopathy. Glucose abnormalities in 
patients with heart failure are common, under-diagnosed, and often associated with 
worsening symptomatic status and poor clinical outcomes (Tang and Young 2001). In 
the RESOLVD (Randomized Evaluation of Strategies of Left Ventricular Dysfunc-
tion) substudy, up to 43% of patients with left ventricular systolic dysfunction had 
documented glucose abnormalities that were often previously undiagnosed (Suskin 
et al 2000). This is in part related to the impaired glucose metabolism associated 
with enhanced sympathetic drive and worsening insulin resistance that is part of the 
pathophysiology of heart failure (Opie 2004).
Diabetes can cause myocyte hypertrophy, interstitial ﬁ  brosis, impaired myo-
cardial blood ﬂ  ow, and increased turnover of free fatty acids, all leading to the 
development of cardiomyopathy and heart failure (Tang and Young 2001). Clinical 
studies have now conﬁ  rmed that patients with heart failure have up to a 4 times 
higher risk of developing diabetes mellitus (Kannel and McGee 1979), and the 
incidence of diabetes in patients with established heart failure has increased over 
previous decades (From et al 2006). Furthermore, the risk of hospitalizations for 
heart failure is greatly ampliﬁ  ed in the patients with diabetes mellitus (Deedwania 
et al 2005).
The mechanism and consequence of insulin resistance in dysfunctional myo-
cardium is currently unknown, but an increasing body of evidence has emerged 
concerning the relationship between heightened sympathetic activation and the 
development of myocardial and peripheral insulin resistance (Parsonage et al 2002). 
In animal studies of advanced heart failure, myocardial insulin resistance is evident 
in the setting of increased sympathetic nervous system activation and oxidative 
stress, directly leading to lipolysis, subsequent alteration in the insulin-signaling 
cascade, and myocyte dysfunction (Nikolaidis et al 2004). In small single-center 
studies, insulin resistance has been linked to systolic heart failure in patients without 
underlying diabetes mellitus. In particular, patients with heart failure have greater Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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impairment in insulin sensitivity compared with matched 
controls (Swan et al 1997; Witteles et al 2004).
Effects of anti-adrenergic therapy 
on glucose metabolism
Glycemic control has been the primary therapeutic target 
for treating patients with diabetes mellitus, even in the 
setting of heart failure (Tang 2006). In the Kaiser registry, 
increasing glycosylated hemoglobin levels portends a higher 
incidence of subsequent heart failure (Iribarren et al 2001), 
an observation that afﬁ  rms data from the United Kingdom 
Prospective Diabetes Study (UKPDS) (Stratton et al 2000). 
Even in the population without diabetes mellitus, elevated 
fasting plasma glucose or glycosylated hemoglobin levels 
have been associated with poorer long-term outcomes in both 
acute and chronic heart failure settings (Bhatia et al 2004; 
Gerstein et al 2005).
Treatment with anti-adrenergic drugs may increase pe-
ripheral vascular resistance, impairing peripheral blood ﬂ  ow 
leading to impaired glucose disposal to skeletal muscles. 
These effects are likely to be ampliﬁ  ed in the setting of 
cardiac insufﬁ  ciency, where vascular changes and neuro-
hormonal upregulation occur as a compensatory response. 
Furthermore, blocking the sympathetic beta-stimulation of 
hepatic glucose production and blunting the symptoms of 
hypoglycemia (such as tachycardia) worsening metabolic 
control may have theoretical adverse consequences.
Clinical studies suggest that various anti-adrenergic drugs 
may carry differential effects on insulin sensitivity (Figure 1). 
One of the earliest investigations compared carvedilol (beta-1, 
beta-2, and alpha-1 selective) with metoprolol tartrate (beta-1 
selective) in diabetic hypertensive subjects. Patients with 
non-insulin-dependent diabetes mellitus received either 
carvedilol (25 mg twice daily) or metoprolol tartrate (50 mg 
twice daily) for a period of 4 weeks and up-titrated as needed. 
After 4 weeks of carvedilol treatment, 23 of 25 patients (92%) 
showed a good response to therapy (reduction of diastolic 
blood pressure below 90 mmHg). Doubling of dosage in 
the carvedilol group did not further increase the response 
rate after another one month of treatment. In contrast, the 
response rate after 4 and 8 weeks of metoprolol treatment 
was 79% and 83%, respectively (Ehmer et al 1988). In 
both treatment groups, blood glucose concentrations and 
glycosylated hemoglobin were maintained within narrow 
limits. Subsequently, the differential effects were demon-
strated in a 12-week isoglycemic hyperinsulinemic glucose 
clamp experiment (the gold standard for assessing insulin 
sensitivity) in patients with essential hypertension, whereby 
insulin sensitivity decreased signiﬁ  cantly by approximately 
14% after metoprolol tartrate but increased after carvedilol 
(Jacob et al 1996). Furthermore, a decrease in high-density 
lipoprotein cholesterol and an increase in triglycerides levels 
were observed in patients in the metoprolol-treated group, 
whereas these parameters remained unchanged in patients 
in the carvedilol-treated group. The explanation of this dif-
ference was the compensatory effects of alpha-1 adrenergic 
blockade in carvedilol that lead to vasodilatation, improved 
oxygen delivery, and reduced insulin release. There is also 
blockade of beta-2 adrenergic stimulation, leading to sup-
pressed substrate preference for non-esteriﬁ  ed fatty acid and 
enhanced insulin signaling. Similar effects are also seen in 
the post-infarction setting (Basat et al 2006), suggesting that 
cardioselectivity of anti-adrenergic therapy may play a role 
in inﬂ  uencing the metabolic proﬁ  le.
Speciﬁ  cally in the setting of heart failure in patients 
without overt diabetes, treatment with carvedilol can lead 
to a signiﬁ  cant decrease in fasting insulinemia as well as 
inﬂ  ammation (Hara et al 2003), and subsequent improve-
ment or unaltered insulin sensitivity (Refsgaard et al 2002; 
Ferrua et al 2005). In animal models, both carvedilol and 
metoprolol succinate had comparable heart rate effects, 
but carvedilol-treated dogs with pace-induced heart failure 
showed signiﬁ  cantly greater increases in stroke volume and 
cardiac output and decreases in left ventricular end-diastolic 
pressure and systemic vascular resistance (Nikolaidis et al 
2006). Furthermore, carvedilol may increase myocardial 
glucose uptake, and may blunt actions of norepinephrine and 
glucagon. These effects clearly illustrate the metabolic ben-
eﬁ  ts of a non-selective adrenergic blockade by carvedilol.
The GEMINI (Glycemic Effects in Diabetes Mellitus: 
Carvedilol-Metoprolol Comparison in Hypertensives) trial 
constituted a milestone in the long-standing debate regarding 
the differential metabolic effects of different anti-adrenergic 
drugs. The GEMINI study randomized 1235 hypertensive 
patients with non-insulin-dependent type 2 diabetes mel-
litus in a 2-to-1 fashion to receive either metoprolol tartrate 
or carvedilol in addition to baseline angiotensin-converting 
enzyme (ACE) inhibitor or angiotensin receptor blocker 
(ARB) and stable anti-diabetic regimens. After 5 months of 
follow-up, the blood pressure effects between the two anti-
adrenergic drugs were comparable. However, an increase 
in glycosylated hemoglobin of 0.15% was observed in the 
metoprolol tartrate arm, whereas an increase in glycosyl-
ated hemoglobin of 0.02% was observed in the carvedilol 
arm (Bakris et al 2004). The separation occurred as early 
as Month 2 of therapy and continued to diverge. Insulin Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Anti-adrenergic therapy in diabetic heart failure
resistance (estimated by homeostatic model assessment or 
HOMA-IR) and microalbuminuria (estimated by urinary 
albumin/creatinine ratio) were also signiﬁ  cantly reduced in 
the carvedilol arm compared with the metoprolol tartrate 
arm. Interestingly, weight gain and bradycardia occurred 
more frequently, and there were more apparent increases in 
triglyceride levels and development of microalbuminuria in 
the metoprolol tartrate arm. Changes in low-density as well 
as high-density lipoprotein cholesterol levels were similar 
between the two groups, although only a small percentage of 
patients were treated with statin therapy. These data conﬁ  rmed 
different metabolic effects among different anti-adrenergic 
drugs, although the results still do not specify the underlying 
mechanisms. Furthermore, there were no long-term outcome 
data to illustrate the clinical consequences of these differences 
in metabolic effects, and the ﬁ  ndings can only be applied to 
the heart failure population by extrapolation.
The role of anti-oxidant properties of anti-adrenergic 
drugs is less clear. Oxidative stress has been implicated in the 
pathophysiology of heart failure, although the mechanisms 
are complex. In both heart failure and type 2 diabetes mel-
litus, reactive oxygen species are increased and endothelial 
nitric oxide synthase is diminished. By reducing nitric oxide 
availability, nitric-oxide derived vasodilatation is reduced, 
which can lead to endothelial dysfunction and poor long-term 
mortality in heart failure (Katz et al 2005). There has been 
evidence to suggest that the transcardiac gradient of plasma 
oxidized low-density lipoprotein is signiﬁ  cantly lower in 
patients who receive carvedilol compared with those who 
do not (Tsutamoto et al 2001). Therefore, the possibility of 
carvedilol as a scavenger of oxidative free radicals, a chelator 
of metal ions, and its ability to improve insulin sensitivity 
through reduction of oxidative stress in patients with diabetes 
mellitus is encouraging, although such relationships have 
yet to be conﬁ  rmed in the human heart failure population 
(Giugliano et al 1997).
Anti-adrenergic therapy in patients 
with heart failure and diabetes 
mellitus
Patients with diabetes mellitus have been included in the 
majority of large-scale clinical trials in chronic heart failure; 
therefore data have emerged regarding the beneﬁ  ts versus 
risks of anti-adrenergic therapy in this population through 
post-hoc analyses. There have been several limitations, 
however, to this work. First, subgroup analyses (even 
when pre-speciﬁ  ed) are often underpowered and poten-
tially biased, in part because diabetes mellitus status has 
not been used as a variable for stratiﬁ  ed randomization. 
Furthermore, diabetes mellitus is often documented as a 
Figure 1 Potential beneﬁ  cial effects of anti-adrenergic blockers in diabetic patients with heart failure.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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dichotomous variable. Therefore, the mere presence of a 
diagnosis of diabetes mellitus cannot provide insight into 
the degrees of glycemic control and vascular abnormalities 
of the patient.
One of the ﬁ  rst published papers in this topic was the 
subgroup analysis from the Second Cardiac Insufﬁ  ciency 
Bisoprolol Study (CIBIS-II) with the use of bisoprolol. 
The relative risk of bisoprolol versus placebo for mortal-
ity was 0.81 (19% reduction, 95% conﬁ  dence interval [CI] 
0.51–1.28) in patients with diabetes mellitus, compared 
with 0.66 (95% CI of 0.54–0.81) in patients without diabe-
tes mellitus (Erdmann et al 2001). These results may have 
been affected by the relatively small sample size of subjects 
with diabetes mellitus in CIBIS-II (only 12% of the study 
population). Meanwhile in the MERIT-HF trial, a larger 
proportion of subjects (n = 985, or 25%) presented with a 
diagnosis of diabetes mellitus, among whom 199 had severe 
heart failure (NYHA III-IV, LVEF 25%) (Deedwania et 
al 2005). A pre-speciﬁ  ed subgroup analysis in the cohort 
of patients with diabetes mellitus demonstrated a mortality 
reduction following treatment with metoprolol succinate 
when compared with placebo (10.1% vs 12.7%, or an 18% 
reduction). This compares with a 31% mortality reduction in 
the non-diabetes subgroup (Deedwania et al 2005). Neverthe-
less, the risk of hospitalization for heart failure was reduced 
by 37% with metoprolol succinate in the MERIT-HF trial. 
One very reassuring point from this report was the lack of 
signiﬁ  cant adverse effects of metoprolol succinate compared 
with placebo in patients with diabetes mellitus, even in those 
with severe heart failure.
The largest experience of anti-adrenergic therapy use in 
patients with chronic heart failure and diabetes mellitus has 
been with the use of carvedilol. Beneﬁ  cial effects of carve-
dilol have been seen across the spectrum of heart failure trials, 
irrespective of the presence or absence of diabetes mellitus. 
A recent meta-analysis summarized this clinical trial expe-
rience with several of the landmark carvedilol heart failure 
studies looking at patients with diabetes mellitus. Among 
a total of 1411 subjects with diabetes mellitus enrolled in 
7 studies (25% of all enrollees), carvedilol demonstrated a 
statistically signiﬁ  cant survival beneﬁ  t (34% risk reduction, 
Figure 2) (Bell et al 2006), even after adjustment for age, 
left ventricular ejection fraction, ischemic etiology, diabetes 
history, and weight. The authors claimed that the number of 
patients needed to treat with carvedilol for 1 year to prevent 
1 death was 23 for the overall population, and 25 for patients 
with diabetes mellitus. These estimates are still more favor-
able than that from SOLVD (estimated number needed to 
treat with enalapril being 78 for 1 year to prevent 1 death) 
(Dries et al 2001).
The latest data came from BEST (Beta-blocker Evaluation 
of Survival Trial), a database of 2708 patients with advanced 
heart failure (36% with diabetes mellitus) randomized to 
bucindolol versus placebo (Domanski et al 2003). While in 
the overall trial bucindolol did not demonstrate a signiﬁ  cant 
survival beneﬁ  t, the use of bucindolol was associated with 
a signiﬁ  cant beneﬁ  t compared with placebo in subjects 
with diabetes mellitus when death plus heart failure 
hospitalizations were combined as endpoints.
Combining the experience of the landmark anti-adrenergic 
therapy clinical trials, several meta-analyses have been 
conducted to determine whether there are differences in mor-
tality and morbidity beneﬁ  ts with different anti-adrenergic 
drugs. All analyses found that patients with chronic heart 
failure and diabetes mellitus had higher event rates compared 
to those without diabetes (Haas et al 2003; Shekelle et al 2003; 
Deedwania et al 2005). In the pooled analysis by Shekelle and 
colleagues, anti-adrenergic therapy use was associated with 
a 23% mortality reduction in patients with diabetes mellitus 
versus a 35% mortality reduction in those without diabetes 
mellitus (Shekelle et al 2003). This ﬁ  nding was consistent 
with a larger meta-analysis, which concluded that anti-adren-
ergic therapy for heart failure was beneﬁ  cial in patients with 
diabetes mellitus (relative risk of 0.84; 95% CI 0.73–0.96; 
p = 0.01, see Figure 2) (Haas et al 2003).
Unanswered questions
It is important to emphasize that while carvedilol appears to 
have favorable metabolic effects over metoprolol or biso-
prolol, all three approved anti-adrenergic drugs can be used 
effectively in the setting of diabetes mellitus. Indeed, there 
is only inferred evidence but no prospective data to support 
the switch from stable regimens of metoprolol succinate or 
bisoprolol to carvedilol in patients with heart failure and dia-
betes mellitus at present. The incremental long-term clinical 
beneﬁ  t of carvedilol in this population over other currently 
approved anti-adrenergic drugs is still debated. In particular, 
several unanswered questions remain despite the wide range 
of studies that have emerged over the years as well as the 
extensive use of carvedilol, bisoprolol, and metoprolol suc-
cinate in the clinical setting.
First, what is the impact of the differential metabolic 
effects of anti-adrenergic drugs on long-term outcomes in the 
clinical heart failure setting? If the underlying pathophysiol-
ogy of heightened risk of developing diabetes in the heart 
failure population is the presence of overactive sympathetic Vascular Health and Risk Management 2006:2(4) 465–475
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disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
Coronary artery disease in women: a review
on prevention, pathophysiology, diagnosis, and
treatment
A
u
t
h
o
r
 
c
o
p
y
 
o
n
l
y
Vascular Health and Risk Management 2007:3(5) 643
Anti-adrenergic therapy in diabetic heart failure
drive (which is counteracted by any anti-adrenergic drug), 
the differences among anti-adrenergic drugs on long-term 
outcomes should be minimal. The carvedilol investiga-
tors have argued that a consistent 35% reduction has been 
observed in both diabetic and non-diabetic subgroups of 
patients with heart failure, particularly in the COPERNICUS 
(Carvedilol Prospective Randomized Cumulative Survival) 
study (Mohacsi et al 2001; Bell et al 2006). They further use 
the results of COMET (Carvedilol or Metoprolol Evaluation 
Trial) to justify their argument, stating that the head-to-head 
comparison in COMET showed a 17% mortality reduc-
tion, a 25% relative reduction in vascular events (stroke 
or myocardial infarction), and a 12% relative reduction in 
the development of new-onset diabetes mellitus with long-
term treatment using carvedilol over metoprolol tartrate in 
patients with chronic heart failure (Poole-Wilson et al 2003; 
Torp-Pedersen et al 2007; Remme et al 2007). However, 
the MERIT-HF investigators responded by demonstrating a 
non-signiﬁ  cant statistical test for treatment interaction in their 
own post-hoc meta-analysis between CIBIS-II, MERIT-HF, 
and COPERNICUS (Deedwania et al 2005).
Second, are there speciﬁ  c subgroups of patients with dia-
betes mellitus that may limit the effectiveness and potentiate 
adverse effects of anti-adrenergic drugs? In other words, are 
there any noticeable differences between insulin-dependent 
versus non-insulin-dependent diabetes mellitus regarding the 
beneﬁ  ts and risks of anti-adrenergic drugs in the heart failure 
setting? What is clear from the clinical trial experiences is 
that irrespective of the type of anti-adrenergic drugs used, 
patients with diabetes compared with those without diabetes 
had signiﬁ  cantly greater weight gain, hyperglycemia, hypo-
glycemia, elevated creatinine levels, syncope, myocardial 
infarction, and cerebrovascular accidents when treated with 
anti-adrenergic therapy. The results from GEMINI and 
many other small mechanistic studies have conﬁ  rmed the 
potential differences in metabolic consequences between 
anti-adrenergic drugs. Hence, there may be theoretical ad-
vantages in using carvedilol in patients with brittle diabetes 
or with evidence of vascular compromise (such as microal-
buminuria).
The United States Food and Drug Administration (FDA) 
has recently added warnings to the label of anti-adrenergic 
drugs (such as carvedilol) regarding their use in patients with 
heart failure and diabetes mellitus. The FDA stated that patients 
subject to spontaneous hypoglycemia and patients with diabe-
tes mellitus receiving insulin/oral hypoglycemic drugs should 
Figure 2 Mantel-Haenszel relative risk (ﬁ  xed effects) plot of anti-adrenergic drugs versus placebo in patients with diabetes mellitus and chronic heart failure for all-cause 
mortality Reproduced with permission from Haas SJ, Vos T, Gilbert RE, et al 2003. Are beta-blockers as efﬁ  cacious in patients with diabetes mellitus as in patients without 
diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J, 146:848–53. Copyright © 2003 Elsevier.Vascular Health and Risk Management 2006:2(4) 465–475
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be warned of the possibility that anti-adrenergic therapy may 
mask manifestations of hypoglycemia (particularly tachycar-
dia), potentiate insulin-induced hypoglycemia, and possibly 
delay recovery of serum glucose levels. Therefore, close 
monitoring of blood glucose levels is advised on initiation, 
adjustment, or discontinuation of any anti-adrenergic therapy 
in patients with diabetes mellitus.
Conclusion
Patients with chronic heart failure and diabetes mellitus 
should be treated with anti-adrenergic therapy because of 
its consistent mortality beneﬁ  ts observed in pivotal trials. 
The differential metabolic effects of carvedilol over other 
anti-adrenergic therapies have largely been implicated by 
logical deduction from experimental heart failure models as 
well as data from two head-to-head clinical trials. Regardless 
of which anti-adrenergic drug is being used to treat chronic 
heart failure, careful monitoring of glycemic parameters and 
adverse effects remains important, particularly in the pres-
ence of diabetes mellitus.
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